132 related articles for article (PubMed ID: 29088766)
1. Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Chüeh AC; Liew MS; Russell PA; Walkiewicz M; Jayachandran A; Starmans MHW; Boutros PC; Wright G; Barnett SA; Mariadason JM; John T
Oncotarget; 2017 Sep; 8(43):74036-74048. PubMed ID: 29088766
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
4. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
5. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas.
Hashimoto K; Nishimura S; Ito T; Kakinoki R; Akagi M
Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35448937
[TBL] [Abstract][Full Text] [Related]
7. The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer.
Konishi J; Toyooka S; Aoe M; Omura Y; Washio K; Tsukuda K; Shimizu N
Oncol Rep; 2004 May; 11(5):1063-7. PubMed ID: 15069548
[TBL] [Abstract][Full Text] [Related]
8. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
Taib N; Merhi M; Inchakalody V; Mestiri S; Hydrose S; Makni-Maalej K; Raza A; Sahir F; Azizi F; Nizamuddin PB; Fernandes Q; Yoosuf ZSKM; Almoghrabi S; Al-Zaidan L; Shablak A; Uddin S; Maccalli C; Al Homsi MU; Dermime S
J Transl Med; 2023 Mar; 21(1):235. PubMed ID: 37004094
[TBL] [Abstract][Full Text] [Related]
9. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
John T; Starmans MH; Chen YT; Russell PA; Barnett SA; White SC; Mitchell PL; Walkiewicz M; Azad A; Lambin P; Tsao MS; Deb S; Altorki N; Wright G; Knight S; Boutros PC; Cebon JS
PLoS One; 2013; 8(7):e67876. PubMed ID: 23935846
[TBL] [Abstract][Full Text] [Related]
10. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
11. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).
Inchakalody VP; Hydrose SP; Krishnankutty R; Merhi M; Therachiyil L; Sasidharan Nair V; Elashi AA; Khan AQ; Taleb S; Raza A; Yoosuf ZSKM; Fernandes Q; Al-Zaidan L; Mestiri S; Taib N; Bedhiafi T; Moustafa D; Assami L; Maalej KM; Elkord E; Uddin S; Al Homsi U; Dermime S
Eur J Pharmacol; 2023 Apr; 945():175612. PubMed ID: 36822455
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 may be a potential target for lung cancer immunotherapy.
Lee L; Wang RF; Wang X; Mixon A; Johnson BE; Rosenberg SA; Schrump DS
Cancer J Sci Am; 1999; 5(1):20-5. PubMed ID: 10188057
[TBL] [Abstract][Full Text] [Related]
13. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
14. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
16. A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer.
Sakai Y; Kurose K; Sakaeda K; Abo H; Atarashi Y; Ide N; Sato T; Kanda E; Fukuda M; Oga T; Noda K; Oka M
Clin Chim Acta; 2021 Aug; 519():51-59. PubMed ID: 33865813
[TBL] [Abstract][Full Text] [Related]
17. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
[TBL] [Abstract][Full Text] [Related]
18. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
19. The role of the NY-ESO-1 in the prognosis of gastric cancer.
Misir Z; Glavčić G; Janković S; Kruljac I; Čugura Filipović J; Čimić K; Ulamec M
Biomol Biomed; 2023 Dec; ():. PubMed ID: 38153439
[TBL] [Abstract][Full Text] [Related]
20. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
